Ginkgo Bioworks (DNA) said Tuesday it has formed a partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign to develop new oral health treatments.
The company said it will use its EncapS technology for ultra-high-throughput screening to identify and evaluate phage-based interventions targeting specific bacteria in the oral microbiome.
Ginkgo Bioworks' shares were 2% lower in recent trading.
Price: 7.63, Change: -0.14, Percent Change: -1.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments